Irvine, CA, United States
Irvine, CA, United States

Allergan, Inc., is an American worldwide pharmaceutical company, focusing on ophthalmic pharmaceuticals, dermatology, neuroscience, urology and cosmetics. Wikipedia.

SEARCH FILTERS
Time filter
Source Type

Patent
Allergan, Inc. | Date: 2017-01-30

Provided are injectable, hyaluronic acid-based hydrogel compositions including conjugated vitamins.


The present invention provides a compound, that is a 1-({halo-2-[(2-hydrocarbyl or substituted hydrocarbyl)oxy]phenyl}methyl)-(fused bicyclic nitrogen heteroaryl) carboxylic acid or an ester or sulfonamide thereof. The compound may be represented by the following formula Wherein R_(1), R_(2), R_(3), R_(4 )A, X, W, Z and Y are as defined in the specification. The compounds may be administered to treat DP, FP, EP1, TP and/or EP4 receptor-mediated diseases or conditions.


Patent
Allergan, Inc. | Date: 2017-05-17

Methods and compositions for detecting BoNT/A enzymatic activity in tissues or a tissue sample are described herein. The invention encompasses antibodies that bind preferentially to BoNT/A cleaved SNAP25 and is able to preferentially detect BoNT/A cleaved SNAP25, as compared to intact (non-cleaved) SNAP25, in a tissue sample.


Patent
Allergan, Inc. | Date: 2017-05-17

Methods for treating inflammation-mediated conditions of the eye are described comprising implanting into the vitreous of the eye of an individual a bio-erodible implant comprising a steroidal anti-inflammatory agent and a bio-erodible polymer.


Patent
Allergan, Inc. | Date: 2017-02-15

The present invention provides a method of detecting whether an implanted fluid-filled prosthetic implant has ruptured, the method comprising the steps of imaging the implant using magnetic resonance imaging and inspecting the magnetic resonance image for defects in the implant, wherein the implant comprises a shell which comprises at least one layer containing a matrix material and an additive distributed therein, the density of the additive being greater than that of the matrix material.


Patent
Allergan, Inc. | Date: 2017-02-01

Disclosed herein are therapeutic methods, compositions, and medicaments related to cyclosporine.


Patent
Allergan, Inc. | Date: 2017-04-05

An elastomeric gel-filled prosthetic implant (10) having a shell made of a single gel barrier layer. The barrier layer (14) is formed of a homogeneous silicone elastomer capable of sterically retarding permeation of the silicone gel through the shell and having a bleed rate that is less than about 40% of the bleed rate of current shells which use a sandwiched construction with an internal barrier layer. Further, the barrier layer shell is made of a material that exhibits a wet strength that is comparable to or greater than current shells. The silicone elastomer may be a polydimethyl siloxane, and the substituted chemical group is a diphenyl group with a minimum mole percent of at least 13%. The implant may be designed for breast reconstruction or augmentation such that the shell is accordingly shaped. The shell wall thickness is at least 0.254 mm (0.010 inches), and desirably about 0.456 mm (0.018 inches). The implant shell may be made by dip-forming, spray-forming, or rotational molding. The exterior may be smooth or textured.


Patent
Allergan, Inc. | Date: 2017-01-23

A headache can be treated more effectively by co-administration of a botulinum toxin and a triptan drug to a patient and/or the effectiveness of a triptan medication can be increased. The botulinum toxin can be botulinum toxin type A and the botulinum toxin can be administered to or to the vicinity of where a patient experiences or is predisposed to experience pain or a headache.


The present invention relates to novel amide derivatives of N-urea substituted amino acids, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of the N-formyl peptide receptor like-1 (FPRL-1) receptor.


Patent
Allergan, Inc. | Date: 2017-01-04

The present disclosure relates to antibodies and polynucleotides encoding the same, which may be used to prevent, control, or reduce the activity of the complement pathway. In addition, the disclosure is directed to compositions and methods for diagnosing and treating diseases mediated by or involving complement Factor Bb. Specifically, the disclosure is related to anti-complement Factor Bb antibodies.

Loading Allergan, Inc. collaborators
Loading Allergan, Inc. collaborators